There are currently 8 active clinical trials seeking participants for Dravet Syndrome research studies. The states with the highest number of trials for Dravet Syndrome participants are Florida, California, Texas and New York.
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770
Recruiting
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/12/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California +45 locations
Conditions: Dravet Syndrome
Register for Updates
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125
Recruiting
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/05/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +40 locations
Conditions: Dravet Syndrome
Register for Updates
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
NCT06118255
Recruiting
The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.
Gender:
ALL
Ages:
Between 1 year and 23 months
Trial Updated:
07/10/2025
Locations: Ep0213 106, Orange, California +18 locations
Conditions: Dravet Syndrome
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA19, Little Rock, Arkansas +91 locations
Conditions: Dravet Syndrome
Register for Updates
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492
Recruiting
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.
Gender:
ALL
Ages:
Between 6 months and 47 months
Trial Updated:
06/10/2025
Locations: UCSF Benioff Children's Hospitals, San Francisco, California +2 locations
Conditions: Dravet Syndrome
Register for Updates
Genetics of Epilepsy and Related Disorders
NCT01858285
Recruiting
Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to epilepsy and related disorders. These findings may help explain the broad spectrum of clinical characteristics and outcomes seen in people with epilepsy.
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Epilepsy, Epileptic Encephalopathy, Ohtahara Syndrome, Infantile Spasms, Dravet Syndrome, Early Myoclonic Epileptic Encephalopathy, PCDH19-related Epilepsy and Related Conditions, KCNQ2-Related Epileptic Encephalopathy, Epilepsy of Infancy With Migrating Focal Seizures (Disorder)
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
GABA Biomarkers in Dravet Syndrome
NCT05651204
Recruiting
This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/13/2022
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Dravet Syndrome
Register for Updates